Investment Rating - The investment rating for the company is maintained as "Buy" [5] Core Insights - The company's performance is driven by the expansion of medical insurance coverage for its key products, Shuwotini and Golixitini, leading to significant revenue growth [1][2] - The company is expected to see accelerated commercialization of its pipeline, with strong differentiation advantages [4] - The revenue forecast for 2025 to 2027 is projected at 7.53 billion, 12.59 billion, and 21.74 billion respectively, reflecting robust growth [4][9] Summary by Sections Performance Overview - In 2024, the company achieved sales revenue of 360 million, a year-on-year increase of 294.24%, with a significant impact from medical insurance price compensation affecting approximately 52 million of the revenue [1] - For Q1 2025, the company reported revenue of 160 million, a year-on-year increase of 96.32%, attributed to the implementation of the new national medical insurance catalog for its core products [1] Product Pipeline and Catalysts - Shuwotini received priority review from the FDA for its new drug application in January 2025, with expectations for approval [2] - Golixitini is set to be launched in June 2024, being the first selective JAK1 inhibitor for treating peripheral T-cell lymphoma, showing promising efficacy and safety [2] - DZD8586 and DZD6008 are innovative products in clinical trials, with data expected to be presented at the 2025 ASCO conference, indicating potential for further advancements [3] Financial Projections - The company forecasts significant revenue growth from 2025 to 2027, with expected revenues of 7.53 billion, 12.59 billion, and 21.74 billion respectively, driven by the commercialization of its key products [4][9] - The projected net profit for 2024 is 846 million, with a decline in subsequent years due to increased costs associated with product launches and development [9]

Core Viewpoint - The company is experiencing significant revenue growth driven by the inclusion of its key products, Shuwotini and Golixitini, in the new national medical insurance catalog starting January 1, 2025, which is expected to accelerate commercialization and data readouts [1][2][5]. Performance Summary - In 2024, the company achieved sales revenue of 360 million yuan, a year-on-year increase of 294.24%, with approximately 52 million yuan of this revenue impacted by price compensation to distributors [2]. - For Q1 2025, the company reported revenue of 160 million yuan, reflecting a year-on-year growth of 96.32%, primarily due to the official implementation of the new national medical insurance catalog for its core products [2]. Catalysts Summary - Shuwotini received priority review from the FDA for its new drug application in January 2025, targeting advanced NSCLC with EGFR Exon20ins mutations, and is expected to be approved as planned [3]. - Golixitini was approved in June 2024 for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in adults, showing promising overall response rates and safety [3]. - DZD8586, a dual-target inhibitor for B-NHL, is expected to present clinical data at the 2025 ASCO conference, showcasing its efficacy and safety [4]. - DZD6008, a new selective EGFR TKI, is in clinical research and aims to address unmet clinical needs in NSCLC, with preliminary data also set to be reported at the 2025 ASCO conference [4]. Profit Forecast and Valuation - The company forecasts revenues of 753 million yuan, 1.259 billion yuan, and 2.174 billion yuan for 2025, 2026, and 2027 respectively, driven by the commercialization of Shuwotini and Golixitini [5].

Core Insights - The report highlights the annual compensation of chairpersons from listed companies in Jiangsu for 2024, showcasing the financial performance and management talent in the region [1][3]. Compensation Rankings - WuXi AppTec's chairman, Li Ge, leads the list with a total compensation of 41.8 million yuan, followed by Taihe Group's Tian Xiaohong with 10.5193 million yuan, marking the only two chairpersons in Jiangsu to exceed 10 million yuan [3]. - A total of 11 chairpersons earn over 5 million yuan, with the pharmaceutical and hardware sectors dominating the high compensation landscape, indicating a strong demand for high-level management talent in high-tech industries [3]. - The semiconductor industry also shows significant compensation levels, with chairpersons from companies like Saiteng Co., Tongfu Microelectronics, and Zhaosheng Microelectronics earning between 3 million and 6 million yuan, reflecting ongoing investments in Jiangsu's chip industry [3]. Gender and Education Disparities - Among the top 100 compensated chairpersons, only one female, Mo Ruoli from Xiangsheng Medical, appears, highlighting the ongoing gender disparity in corporate leadership roles [3]. - There is a strong correlation between educational background and compensation, with many top earners holding doctoral degrees, such as Li Ge (WuXi AppTec) and XIAOLIN ZHANG (Dizhe Pharmaceutical-U) [3]. Age Distribution - Over 50% of the chairpersons are aged between 50 and 60, with those born in the 1970s becoming the main management force. The youngest chairpersons are from Kangli Elevator, Baoli International, and Jujie Microfiber, all aged 32 [3]. Performance and Compensation Concerns - Despite the high compensation figures, there are concerns regarding the alignment of pay with company performance, particularly for ST companies like ST Huifeng and ST Yigou, where the chairpersons' salaries do not correspond with the companies' financial struggles [4].

Summary of Key Points Core Viewpoint The article discusses the changes in the secretary positions of A-share listed companies in Wuxi, highlighting the salary rankings of these secretaries for the year 2024, as well as the turnover rate of secretaries in the region. Group 1: Overview of Wuxi A-share Listed Companies - Wuxi has a total of 124 A-share listed companies, with 95 secretaries having served before 2024 [1] - Since the beginning of 2024, there have been 29 new secretaries, resulting in a turnover rate of 23.39%, which is higher than that of Nanjing and Suzhou [1] Group 2: Salary Rankings of Secretaries - The highest-paid secretary in Wuxi for 2024 is Lü Hongbin from Dize Pharmaceutical, with a total salary of 4.21 million yuan, an increase from 4.07 million yuan in 2023 [4][8] - The second highest is Wu Guoyi from China Resources Microelectronics, earning 2.62 million yuan, slightly up from 2.60 million yuan in 2023 [4][8] - Other notable salaries include Yang Erli from Xiexin Energy at 1.86 million yuan and Zhang Yuanzhou from WuXi AppTec at 1.55 million yuan [4][8] Group 3: Notable Secretary Profiles - Lü Hongbin, born in 1978, has a background in investment banking and has held various significant positions in the industry before becoming the secretary at Dize Pharmaceutical [3] - Wu Guoyi, aged 48, has been the secretary at China Resources Microelectronics since April 2019 and is the second highest-paid secretary in Wuxi [3] Group 4: Salary Comparison and Trends - The salary data indicates a general increase in compensation for secretaries compared to the previous year, with several secretaries seeing significant jumps in their earnings [4][8] - The trend of hiring from investment banking for secretary positions continues, reflecting a competitive job market for these roles [3]

中国经济网北京5月12日讯迪哲医药(688192.SH)今日收报52.23元，跌幅7.36%。该股目前处于破发状 态。 迪哲医药于2021年12月10日在上交所科创板上市，发行股票4000.01万股，发行价格为52.58元/股。 迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。迪 哲医药最终募集资金净额比原计划多2.03亿元。该公司于2021年12月7日披露的招股说明书显示，其拟 募集资金17.83亿元，拟分别用于新药研发项目和补充流动资金。 迪哲医药首次公开发行股票的保荐人(主承销商)为中信证券股份有限公司，保荐代表人为丁元、彭浏 用，联席主承销商为华泰联合证券有限责任公司。该公司发行费用总额为1.17亿元，其中，承销费及保 荐费9564.42万元。 迪哲医药4月22日发布的2023年度向特定对象发行A股股票上市公告书显示，根据立信会计师事务所(特 殊普通合伙)2025年4月10日出具的《验资报告》(信会师报字[2025]第ZA10726号)，本次发行最终获配发 行对象共计14名，发行价格为43.00元/股，本次发行数量为41,764,808股，募集资金总额 ...

Core Viewpoint - The article discusses the disparity in employee compensation within the A-share pharmaceutical and biotechnology sector for the year 2024, highlighting the highest and lowest average salaries among companies in the industry. Group 1: Highest Average Salaries - The top ten companies with the highest average employee salaries in the pharmaceutical and biotechnology sector are predominantly innovative drug companies, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - The average salary of BeiGene's R&D personnel is 956,000 yuan, with domestic R&D personnel earning an average of 592,000 yuan and overseas R&D personnel earning 1,586,000 yuan [2] - Other companies in the top ten include Dizal Pharmaceutical (迪哲医药) with an average salary of 686,700 yuan and Yihong Pharmaceutical (亚虹医药) with an average salary of 627,400 yuan [2][3] Group 2: Lowest Average Salaries - The ten companies with the lowest average salaries in the sector have an average salary as low as 70,500 yuan, with the lowest being 70,500 yuan at Yisheng Pharmaceutical (益盛药业) [7][9] - The majority of these low-salary companies are traditional Chinese medicine firms and offline pharmacy businesses, with four being Chinese medicine companies [10] - Companies like Teva Pharmaceutical (特一药业) reported a significant decline in net profit, leading to a 10.1% decrease in average salary compared to 2023 [11] Group 3: Salary Trends and Industry Insights - Among the 498 companies in the pharmaceutical and biotechnology sector, 49 companies have an average salary above 300,000 yuan, while 144 companies fall between 200,000 to 300,000 yuan [8] - The article notes that the average salary for most innovative drug companies has increased compared to 2023, with the highest increase being 13.62% for Ailisi (艾力斯) [6] - The article also highlights the challenges faced by offline pharmacies, with a significant drop in customer traffic and profitability due to changes in healthcare policies and increased competition [11][12]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-30 迪哲（江苏）医药股份有限公司 关于董事兼高级管理人员减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持有的基本情况 本次股份减持计划实施前，迪哲（江苏）医药股份有限公司（以下简称"公 司"）董事长兼首席执行官张小林（ZHANG XIAOLIN）博士直接持有公司股份 7,310,972 股，占公司目前总股本的 1.5913%。上述股份中 7,150,000 股来自股权 激励计划行权，160,972 股来自二级市场集中交易竞价增持。 减持计划的实施结果情况 2025 年 1 月 21 日，公司披露了《迪哲医药：关于董事兼高级管理人员减持 股份计划公告》（公告编号：2025-04）（以下简称"《减持计划"》），因偿 还借款等个人资金需求，张小林博士拟通过集中竞价交易或大宗交易方式合计减 持公司股份不超过 1,827,000 股（含本数），占公司总股本的比例不超过 0.4374%， 自减持计划披露之日起 ...

Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

保荐总结报告书 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 保荐机构名称 华泰联合证券有限责任公司 保荐机构编号 Z26774000 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 栋 B7 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 | | 联系人 | 许超、丁明明 | | 联系电 ...

根据《证券法》、《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为迪哲（江苏）医药股份有限公司 （以下简称"迪哲医药"或"公司"）2023 年度向特定对象发行 A 股股票的保 荐机构，承接公司首次公开发行的原保荐机构中信证券股份有限公司未完成的持 续督导工作，对迪哲医药进行持续督导，并出具本年度持续督导跟踪报告。 一、保荐机构和保荐代表人发现的问题及整改情况 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 2024年年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：迪哲医药 | | --- | --- | | 保荐代表人姓名：许超 | 联系电话：010-56839300 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | 随着研发投入的增加，报告期内公司仍处于亏损状态。公司针对不同靶点研 制多款产品，未来仍需持续较大规模的研发投入用于在研项目完成临床试验、药 学研究、临床前研究及新药上市前准备等产品管线研发业务。此外，公司 ...